ProCE Banner Activity

FAKTION: Updated and Expanded Analysis of Fulvestrant + Capivasertib or Placebo After Aromatase Inhibitor Therapy in ER+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
Results from the randomized phase II FAKTION trial showed that the addition of capivasertib to fulvestrant prolongs survival in ER+/HER2- advanced breast cancer and suggest that capivasertib primarily benefits patients with PI3K/AKT/PTEN pathway alterations.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab